pneumococcal polysaccharide and protein conjugate vaccines

This combination refers to a maternal and infant immunization strategy evaluated by the Johns Hopkins Bloomberg School of Public Health in the Mother's Gift trial (NCT00142389). The regimen involves the sequential administration of two distinct biologics: the 23-valent pneumococcal polysaccharide vaccine (PPV23, specifically Pneumovax 23) given to pregnant women during the third trimester, followed by the pneumococcal conjugate vaccine (PCV, specifically Prevnar) administered to their infants at 6, 10, and 14 weeks of age. The strategy is designed to provide early protection to infants against Streptococcus pneumoniae through both transplacental antibody transfer from the mother and active infant immunization. This approach targets invasive pneumococcal diseases, including pneumonia, meningitis, and bacteremia, particularly in resource-limited settings where the burden of infant pneumococcal disease is high.

Brand names

PneumovaxPrevnar

Other names

23-valent pneumococcal polysaccharide vaccinepneumococcal conjugate vaccinePPV23PPV-23PPV 23PCV7PCV-7PCV 7Mother's Gift study vaccines